Powered by
-
BMRN Stock Chart
Historical BMRN Prices
Biomarin Pharmaceut Stock Analysis
Rating: Hold
Total Grade: C
Analysis Breakdown
| BMRN Stock Grade: | C |
| Fundamental Grade: | C |
| Quantitative Grade: | C |
| BMRN Earnings | |
| Earnings Growth: | C |
| Earnings Momentum: | C |
| Earnings Surprises: | A |
| Analyst Earnings Revisions: | C |
| BMRN Financial Information | |
| Sales Growth: | B |
| Operating Margin Growth: | C |
| Cash Flow: | B |
| Return on Equity: | D |
Biomarin Pharmaceut Stock: Weekly View
| This Week: | C |
|---|---|
| Last Week: | C |
| Two Weeks Ago: | C |
BMRN Stock predictions, Articles, and Biomarin Pharmaceut News
- From InvestorPlace
- From the Web
-
18 Stocks That Could Be Takeover Targets - July 10, 2018
These takeover stocks all look like promising takeover targets at a time when M&A activity is likely to pick up. Continue…
-
3 Biotech Stocks Up in the Past Month on Industry Turnaround - June 15, 2018
We take a look at three biotech stocks whose share price has increased in the past month due to as the biotech industry bounced back in the past month after dec.... Continue…
-
5 Biotech Stocks to Boost Your Portfolio’s Health This Year - May 31, 2018
Though the biotech industry is down this year, there are still a few stocks which can strengthen your portfolio. Compare Brokers.... Continue…
-
4 Biotech Stocks With Leaky Pipelines - April 10, 2018
A strong pipeline can make or break biotech stocks, ensuring strong profits for years to come. These four biotech companies don't make the cut. Continue…
-
5 Biotech Stocks With Amazing Pipelines - March 27, 2018
Biotech stocks are only as good as their pipeline. These five biotech companies are about to put out promising new drugs, with more products in the works. Continue…
-
Why BioMarin Pharmaceutical Inc. Stock Is Surging Today - December 11, 2017
BioMarin (BMRN) stock was on the rise today following positive news for its gene therapy efforts to treat severe hemophilia. Continue…
-
Earnings Growth Make BioMarin Pharmaceuticals (BMRN) a Sell - November 6, 2017
Portfolio Grader currently ranks BioMarin Pharmaceuticals (NASDAQ:BMRN) a Sell. Using Louis Navellier's investing methodology, this analytical tool researches stocks by means of fundamental and quantitative analytical tools. BMRN has maintained this ranking for 4 months. Continue…
-
3 Big Stock Charts for Wednesday: Twilio Inc (TWLO), BioMarin Pharmaceutical Inc. (BMRN) and Mondelez International Inc (MDLZ) - August 23, 2017
BioMarin Pharmaceutical (BMRN), Mondelez International (MDLZ) and Twilio (TWLO) are all teetering on the brink of bearish signals. Continue…
-
Wall Street’s 5 Hottest Biotech Stocks Right Now - July 17, 2017
These five top biotech stocks have the seal of approval from the Street, with 'strong buy' analyst consensus ratings and big upside. Continue…
-
3 Pivotal Drug Trials to Watch for Explosive Potential - June 29, 2017
Here's a look at three biotech stocks that have at least one treatment prepped to enter pivotal clinical trials soon. Continue…
